Yesterdays results look good, it's just a pity they couldn't make that maiden profit. At least OXB income is moving in the right direction, and costs seem to be under control ,but that will change next year ,as R/D will climb again as the Phase I/II clinical study for OXB-102 Parkinson's disease program moves forward .I have one question asI'm not quite sure what they mean by Partnering discussions are ongoing for OXB's in-house priority development programmes, with a planned spin-out legal structure to be established for ocular products, are they planning to start another limited company, and if so ,who will own it and control it ?
15 Mar 2018 07:01:09
Oxford Biomedica PLC
RNS Number : 8065H
Oxford Biomedica PLC
15 March 2018
OXFORD BIOMEDICA PLC
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017
Oxford, UK - 15 March 2018: Oxford BioMedica plc ("OXB" or "the Group"; LSE: OXB), a leading gene and cell therapy group, today announces preliminary results for the 12 months ended 31 December 2017 and a post-period update.
FINANCIAL HIGHLIGHTS (INCLUDING POST PERIOD END)
- Gross Income1 increased by 28% to £39.4 million (2016: £30.8 million)
- Operating expenses excluding depreciation and amortisation and share based payments decreased by 12% to £22.9 million (2016: £26.1 million)
- EBITDA loss significantly reduced to £1.9 million (2016: £7.1 million)
- EBIDA (EBITDA adjusted by the R&D tax credit) profit of £0.8 million (2016: £3.4 million loss)
- Operating loss for the period reduced 50% to £5.7 million (2016: £11.3 million)
- Cash outflow before financing activities reduced by £9.2 million to an inflow of £1.0 million (2016: £8.3 million outflow)
- Capital expenditure reduced to £2 million (2016: £6.4 million)
- Debt refinanced on significantly improved terms with $55 million Oaktree Capital facility
- A charge of £3.9 million (2016: Nil) was incurred upon the termination of the Oberland loan facility
- Cash at 31 December 2017 of £14.3 million2 (2016: £15.3 million)
- Successful £20.5 million (gross) equity Placing to fund further bioprocessing capacity to service anticipated increased demand
(1) Gross Income is the aggregate of revenue (£37.6 million) and other operating income (£1.8 million) (2016: £27.8 million and £3.0 million respectively)
(2) Includes $5m ring fenced under Oaktree agreement
Leading LentiVector® delivery platform for gene and cell therapy partnerships
- Major commercial supply agreement signed with Novartis for the lentiviral vector to produce CTL019 (tisagenlecleucel, brand name Kymriah) and additional CAR-T products; over $100 million revenue potential over three years
- $105 million collaboration and licence agreement completed with Bioverativ to access OXB's LentiVector® platform and manufacturing technologies for haemophilia gene therapies
- Lentiviral vector demand is increasing and the Group is in several discussions regarding a range of additional collaborations
Novartis' product Kymriah
- First ever LentiVector-Enabled product approval for the Novartis product Kymriah (tisagenlecleucel) in children and young adults with r/r B-cell acute lymphoblastic leukaemia (ALL) in the US
- Kymriah sBLA submitted in the USA by Novartis in r/r diffuse large B-cell lymphoma (DLBCL) in adults; product undergoing expedited review under breakthrough designation
- CTL019 European Marketing Authorisation (EMA) Application filed by Novartis for r/r B-cell ALL in children and young adults and for r/r DLBCL in adults
- Primary analysis of results from the pivotal JULIET trial demonstrating that Kymriah (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
- US FDA Priority Review for Kymriah for adults with r/r DLBCL and EMA accelerated assessment for childr
Hi Mole 42 it's been awhile since we last spoke .
As you know Mole I have all ways supported OXB as a company ,and have all ways defended its technology, I must admit though ,that over the years there have been a few challenging times, but for some reason it's product stood out above the rest for me , and new one day it would come good, and it has .
I like many others here could see a good future for OXB, and for my investment, so thanks Mole for your kind words, lets hope OXB continues to prove it's doubters wrong .
Hi Mole 42 it's been awhile since we last spoke .
As you know OXB I have all ways been a supporter of this technology and OXB inarticulate, over the years there have been quite a few challenging times, but for some reason it's product stood out above the rest, so I just new it would come good one day , just as many others have , and I like many others ,I could see a good future for the company eventually and for my investment, so thanks Mole for your kind words, lets hope OXB continues to prove it's doubters wrong .
Fantastic news ; very positive on future manufacturing deals and in-house
The Company expects OXB-102 (Parkinson's disease) to advance into clinical development in H1 2018. The Board expects to spin out / out-license at least one of the Group's in-house product candidates before the end of 2018
Well I'm not surprised at this placing ,and for once ,I'm quite pleased a placing is to be made ,This placing will enable OXB to continue it's accelerated growth over the next few years, with confidence. The future is ours at last, I just wish they could have purchased the facility rather than lease it .
The Company is proposing to raise approximately £20.5 million through the issue of up to 174,346,817 new ordinary shares at a price of 11.75 pence per Placing Share.
The Placing is being conducted through an accelerated bookbuild process (the "Bookbuild") which will commence immediately following this announcement. Peel Hunt and WG Partners are acting as joint bookrunners in respect of the Placing.
The timing of the closing of the Bookbuild and allocations are at the discretion of the Joint Bookrunners, in consultation with the Company, and will be decided at the close of the Bookbuild. Details of the outcome of the Bookbuild will be announced as soon as practicable after close of the Bookbuild.
The Placing is not underwritten. The Placing Shares are not being made available to the public and none of the Placing Shares are being offered or sold in any jurisdiction where it would be unlawful to do so.
The Placing is subject to the terms and conditions set out in the appendix (the "Appendix") to this announcement (which forms part of this announcement, such announcement and the Appendix together being, this "Announcement").
The Placing is conditional upon, inter alia, the placing agreement entered into between the Company, Peel Hunt and WG Partners becoming unconditional in accordance with its terms and not having been terminated prior to Admission.
Application has been made by the Company to the UK Listing Authority and the London Stock Exchange for up to 174,346,817 ordinary shares of 1 pence each in the Company to be admitted to the premium listing segment of the Official List of the UK Listing Authority and to be traded on the Main Market of the London Stock Exchange. The shares will be issued fully paid and will rank pari passu in all respects with the existing issued ordinary shares of 1 pence each of the Company. It is expected that admission of the shares will become effective at 8.00 a.m. on 14 March 2018, and that dealings will commence at that time.
Background to the Placing
The growing multi-billion dollar gene and cell therapy market has seen three therapies approved in the last six months, including Novartis' Kymriah, with Oxford BioMedica having the potential to receive in excess of $100 million over the next three years for supply of vector to Novartis in relation to Kymriah. There are potentially seven more therapies to be approved in the next few years.
Oxford BioMedica is the first and only commercial supplier of lentiviral vectors to the gene and cell therapy market. The Company estimates that the lentiviral vector bioprocessing market was worth approximately $200 million in 2017 and is expected to grow at a 15.4 per cent. compound annual growth rate from $158 million in 2015 to $800 million by 2026. These estimates exclude milestones and royalties from partnerships which may be earned by companies operating in this space.
In recent months Oxford BioMedica has been experiencing a step change in business development enquiries for its expertise across the LentiVector enabled platform and Oxford BioMedica has a strong IP position, know-how and expertise across that platform. The Company has successfully developed a new 200 litre manufacturing process with significant productivity improvements to address current and future demand across the main indications. Oxford BioMedica believes a new affordable full service site will meet expected long-term demand, create dual source manufacturing for partners and significantly increase capacity to a level competitive with other market participants.
The Placing will provide funds to exploit the current mark
An Oxford University spin-off that specialises in gene therapy applications has won a $100 million contract from Bioverativ, an American company specialising in treatments for haemophilia.
Shares in Oxford Biomedica rose 11.7 per cent to 12p after it announced the deal, under which it will receive $5 million immediately and milestone payments worth up to $100 million.
It is the second major deal in seven months for the company, which was spun off from Oxford University in 1995, early in the gene therapy revolution. It floated on the Alternative Investment Market in 1996, moving to the official list of the London Stock Exchange in 2001.
Last July it signed a three-year deal that could be worth more than $100 million with the Swiss drugmaker Novartis to supply material for a new treatment for leukaemia.
In both deals Oxford Biomedica will supply lentivectors, which are used to insert genes into human cells. Oxford Biomedica is also in line to receive royalties on sales of the companys haemophilia products.
Analysts at Peel Hunt said yesterdays deal cemented their view that Oxford Biomedicas technology was at the forefront of the gene and cell therapy revolution.
Sorry once again posted wrong post Sorry
--------------------------------------------------------------------------------------------------------------------I know many on this board were very annoyed when the present board decided to stop chasing rain bows, and started concentrating on producing a product that could bring in an income, to ensure OXB could survive.
The Bod that followed and those who put their own cash into this company I believe stopped OXB going bust, and they should be thanked for that, and yes it did meant OXB had to change direction , from the days of Professor Kingsman and his wife, who founded this company, they did such a great job for OXB in the early years ,especially with their expertise in Biologics and DNA ,and yes they were trail blazers that gave OXB a future , and again, we have to thank them for what they did for the company while they were in charge ,but they were only interested in R/D, and that did not produce the revenues we needed as a company to keep going
.Just looking back at the 2000 accounts, back then ,OXB had only just started clinical trials with MetXia, and Tro- Vax they were just about to enter clinical development, and OXB were still awaiting approval for the phase 1/11 trial for colorectal cancer, neither product produced a penny in revenue for OXB , so both products have now been put on hold, or dropped, and after twenty years of R/D and hundreds of millions of pounds spent on them, they have produced nothing in revenue .
The company had to find another way forward, so they moved away from R/D and expanded into the manufacturing of our own Lentivector, and its already paying us back ,and it will continue to do so for the foreseeable future ,OXB plant is the only one in the world that can produce this product ,yes there are other vectors out there ,but they are owned by the big pharmer,s ,and they need everything they can produce for their own products ,that leaves OXB as the only independent company in this area of expertise to take up the slack from all the other companies out there, who require this kind of technology .
The Novates contract alone will put OXB into profit, it's estimated their contract alone is worth around £100m, and could be as high as £1billion over 10 years, that means OXB will continue to grow over that time, and is where we will get the cash to fund our future R/D , I/E cash to support products such as Tro -Vax .
I personally can't see any reasons why O.X.B should return to its shareholders for more cash, and that's why the Government are now backing OXB, as it needs companies like ours to help new companies get established in the UK they also to see OXB as a way of helping start-ups in this industry, that's why they are backing OXB with grants ,and appointing them as their manufacturing partner in Biotech , and I Like Crisisurfer believe this is why the value in OXB is now locked in ,and it will grow even stronger as new contracts are signed .
Genomics is the future and the government know that, and they are determined that the UK will stay at the forefront of the competition ,and to prove that, a new Government backed project for new Bio start-ups is being built in Reading right now , its near junction 12 of the M4, and the university of Reading are backing the project, and will help those who want to take space there , already there are two very large blocks of new labs being built and will accommodate many new Bio start-ups in the future ,all of who will need our product and advice in the future .
The future is ours
I know many on this board were very annoyed when the present board decided to stop chasing rain bows, and started concentrating on s producing a product that could bring in an income, to ensure OXB could survive .
This Bod, and those who put their own cash into this company to stop it going bust should be thanked, even though it meant OXB had to change from the days of Professor Kingsman and his wife who founded this company, and did such a great job in the early day with their expertize in Biologics they were trail blazers back then, and we have to thank them as well for what they did ,but they were only interested in R/D and that did not produce the revenues to keep OXB afloat .
Just looking back at the year 2000 accounts, they had only just started clinical trials with MetXia, and Tro- Vax was just about to enter clinical development ,and was awaiting approval for a phase 1/11 trial in colorectal cancer, and neither product produced a penny in revenue, so both products have now been put on hold, or dropped , after twenty years of R/D and hundreds of millions of pounds spent on them.
The company now has moved on from being a R/D company , but has expanded into the manufacturing of Lentivector its all ready paying back some of our investment ,and it will continue to do so ,as its the only plant in the world that can produce this product ,yes there are other vectors out there ,but they are owned by the big pharmer,s who need what production they have for their own products ,leaving OXB as the only independent company in this area of expertize to take up the slack from all the other companies out there that require this technology .
Novates alone will put OXB into profit as it's estimated their contract alone is worth some where between £100m and £1 billion when in full production ,that means OXB will continue to grow over the next 10 years , and that is where we will get the cash to fund our future R/D for products such as Tro -Vax .
I personally can't see any further reasons for O.X.B to return to it shareholders asking for more cash,that's why the Government are now backing OXB and are backing both the company and it's now how because they to see OXB as the for runner to other start ups in this industry and that's why they are backing OXB with grants ,and Like Crisisurfer I also believe that the value in OXB is now locked in ,and it will grow stronger as new contracts are signed .
Genomics is the future, and the government know that ,and they are determined that the UK stays in front of the competition .And to prove that, a new Government backed project for new Bio start ups is being built in Reading, near to junction 12 of the M4, the university of Reading are also backing the project and will help those who take space , all ready there are two very large blocks of labs being built ,this will accommodate many new Bio start ups ,who will also need our product .
The future is good for OXB
Hmmmmm...yes Russian Oligarchs might learn to fly? But yes I doubt it too.
What has surprised me is that for this company the UK government has learnt to fly. Support in the form of loans and grants at vital times, especially recently, as OXB face up to the existential challenge of scaling up and industrialising the processes required.
OXB is one of the only places in the world that can do this, and UK Gov get that!
Therefore assigning value to the company is more difficult than most other pharma including start ups! For example how many start ups have proof of concept for such an industry changing technology, and control over the manufacturing technology, which is in itself a potentially huge asset?
OXB could be taken over, but I hope not. If they survive take over risks then they could start to acquire significant long term value from here.
One thing is for sure. Their value is now tied at the hip with emergence of a whole new pharma sector and frontier. OXB helped makes this happen and I for one am sure glad that they are at the front of it. I am also certain that conventional analysis doesnt make it easy to value this company. I suspect however that (barring unforeseen calamity) the current value is now locked in, and for me that makes it a buy!
Any company that has changed medicine in the face of Big Pharma has already punched above its weight! My gut instinct, based on the above, is that OXB will now go North from here.
Yes S17 I would agree that from an altruistic viewpoint it is excellent that money has been provided for OXB in their past fundraisings and that more will likely be provided in future fundraisings. I wish that wealthy oligarchs from Russia and the middle east would put their money into worthwhile ventures such as this rather than football clubs! OXB's trailblazing work has achieved a huge amount not only from a scientific viewpoint, but also in terms of future benefits for mankind. I think your timescale for potential benefits to shareholders of about 5 to 10 years is about right, unless they (or their potential spin-off vehicles) can raise significant amounts of money to accelerate product development.
About 1998-9 I warned about short termism and said give it 10 years. I'd not have expected it to take 20+ and counting, but what a tribute to those who've managed to convince so many to keep on stumping up cash to fund the annual losses. In the meantime we seem to be making significant scientific progress to help mankind.
I'm hoping to live long enough to benefit financially, but in the meantime I'm content to have provided some support from the very early days. Give it another 5-10 years.
Another big agreement for OXB but still following the pattern of a small up front payment with enormous amounts of jam tomorrow. This, of course, is the nature of OXB's business model but it is not a very attractive one. The financial upside to the products it is developing do little more than support its running costs. However I am beginning to get a bit more interested as I think the company is reaching a position where it can at least sustain itself, but if anyone knows when it will reach a position of sustainable profit growth, please let me know!
Indeed, it's been a roller coaster ride for long term holders, a bit touch and go on a few occasions, but I think there is no stopping us now, leaders in the field with lots of manufacturing capability we should see our rewards shortly, and fantastic treatments coming on stream for awful diseases as a bonus!
Interesting article questioning the pricing of Kymriah.
Exciting times ahead for OXB assuming Novartis get approval and great to see such impressive results todate in the treatment of this type of cancer.
Having bought shares in OXB some as high as 49p and others as low as 3p (average now 12p) I'm very close to finally seeing a paper profit having held for almost 15 years.
Best wishes those who have kept the faith and to all who have contributed to this discussion board here over the years.
Yes agree with you that the companies behind the delivery system never gets the credit they deserve. I felt the interview was half way there. I sometimes think OXB are pretty sleepy when it comes to PR!
Regarding OT, yes were still going and growing. The website is at www.blue-sky-therapies.com . Were really Devon and Cornwall based and do mostly sensory processing and neurodevelopmental paediatrics, but adult referrals are increasing. Do feel free to pass on details or get in touch via website. Wed be happy to help in anyway we can even if its just a chat and pointers to what the opportunities are like in the private sector.
Thanks also for all your great posts. Theyve kept me going on this share when patience has been at a premium :-)
Hi Crisisurfer they never talk about OXB when they talk about cart T ,I have read hundreds of reports about Cart T over the years ,but non of them mention the delivery system , it can be very frustrating at times as they seem to think they own the system.
And to be honest they might as well ,as I have not seen any body else signing contracts recently to use our Lentifactor , which seems a bit odd to me ,as the press keep telling every one, that there is shortage of systems like Lentifactor out there and because of that shortage its holding gene therapy back ,yet OXB say, they would be able to take on more work should any body want to use their services strange that ..
There must be gremlins in the water
Crissis surfer Some time ago you spoke to me about your O/T agency ? are you still running it ? if so, my daughter would be interested in joining you .Do you have any work in the south of England ? she was working in children's services doing full assessments and grants for planning, she is also a registered trainer regarding other staff ,and equipment including hoists .
Received this info just a few minutes ago there's some Interesting info about time lines and manufacturing .
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81%
Event-free survival and overall survival at six months were 73% and 90%, with median duration of remission not reached
Kymriah was detected in patients up to 20 months, demonstrating long-term persistence
Novartis is committed to bringing Kymriah to more patients with a regulatory application currently under review by the EMA for r/r ALL and r/r DLBCL based on Novartis global clinical trial program, including ELIANA
The digital press release with multimedia content can be accessed here:
Basel, January 31, 2018 - Novartis today announced updated results from the pivotal ELIANA clinical trial of KymriahTM (tisagenlecleucel), formerly CTL019, in relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) have been published in The New England Journal of Medicine (NEJM). New data include longer-term follow-up and efficacy in 75 infused patients, analysis of expansion and persistence of Kymriah, and longer-term safety. Kymriah became the first chimeric antigen receptor T (CAR-T) cell therapy to receive regulatory approval in August 2017, when it was approved by the US Food and Drug Administration (FDA) for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse, based on previous results from the ELIANA study, which was conducted in collaboration with the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP).
In the analysis of 75 infused patients with three or more months of follow-up, Kymriah demonstrated an overall remission rate of 81% (95% CI: 71% - 89%). Sixty percent of patients achieved complete remission (CR) and 21% of patients achieved CR with incomplete blood count recovery (CRi), with no minimal residual disease (MRD) detected among all responding patients (95% [58/61] by day 28). Median follow-up was 13.1 months.
"Kymriah, the first FDA-approved CAR-T cell therapy, has shown the potential to be a definitive therapy, providing early, deep and durable remissions for children and young adults with relapsed or refractory ALL," said Samit Hirawat, MD, Head, Novartis Oncology Global Drug Development. "These data are a testament to our commitment at Novartis for continued CAR-T cell therapy research to bring this therapy to as many patients as possible."
Among patients who achieved CR/CRi, median duration of response was not reached. Remissions were durable with six-month relapse-free survival of 80%. Event-free survival was 73% at six months (95% CI: 60%-82%) and 50% at 12 months (95% CI: 35%-64%), with median event-free survival not reached. Overall survival in the 75 infused patients was 90% (95% CI: 81%-95%) at six months, and 76% (95% CI: 63%-86%) at 12 months. Kymriah was detected in patients up to 20 months. Median persistence of Kymriah was 168 days (range: 20-617; n=60 patients with CR/CRi) at data cutoff. All responding patients demonstrated B-cell aplasia (a low number of or absent B-cells), an on-target effect of treatment with Kymriah, and most received immunoglobulin replacement per local practice. Evaluable patients with a response at day 28 had a median time to maximum expansion of 10 days (5.7-28 days; n=60), whereas six patients with no response had a median time to maximum expansion of 20 days (13-63 days). Kymriah uses the 4-1BB costimulatory domain in its chimeric antigen receptor, which has shown to enhance early cellular expansion and long-term endurance of CAR-T cells.
Today Novartis have released their NEJM publication updating the analysis from the ELIANA trial it shows longer-term durable remissions with Kymriah(TM) in children, and young adults with r/r ALL .
to read this document please go to
Novartis have issued their accounts for the past 3 months and they say they have launched 33 treatment rooms
launch in the US progressed well in the fourth quarter. 33 treatment centers are now REMs certified, 25 of those are fully operational and we are focused on ensuring access for patients
Regulatory submissions and filings (in Q4)
Kymriah (tisagenlecleucel, formerly CTL019) filed with FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) who are ineligible for or relapse after autologous stem cell transplant (ASCT), and with EMA for adult patients with r/r DLBCL who are ineligible for autologous stem cell transplant and children and young adult patients aged 3 to 25 years with relapsed or refractory B cell acute lymphoblastic leukemia. FDA granted Priority Review and EMA granted accelerated assessment of the submission.
ACZ885 (canakinumab) submitted supplemental Biologics License Application and Marketing Authorization Application for cardiovascular risk reduction to the FDA and EMA.
Sandoz proposed biosimilar pegfilgrastim (Amgen's Neulasta®) was accepted for regulatory review by EMA.
Sandoz proposed biosimilar adalimumab (AbbVie's Humira®) was accepted for regulatory review by FDA in January.
The government have awarded OXB with a £3m award, in order to support our viral vector manufacturing facility.
01/23/2018 | 01:04pm GMT
London, UK - 23 January 2018: Oxford BioMedica plc ('Oxford BioMedica' or 'the Group') (LSE:OXB), a leading gene and cell therapy group, has announced it that has been awarded a £3 million grant by the UK's innovation agency, Innovate UK, to support the UK's efforts to produce viral vectors and ensure adequate supply to meet future demand. Reference: corresponding Innovate UK announcement here: https://www.gov.uk/government/news/improved-healthcare-for-all-pioneering-projects-get-funding
The aims of this grant are closely aligned with the current government national priorities to make the UK a global hub for manufacturing advanced therapies, which will benefit economic growth and create and retain more highly skilled employment.
The grant will be used to support investment in equipment for vector development, vector manufacture, storage and analytical equipment, as well as other items that are key for the operation of vector GMP facilities. In addition, a small part of the grant will be used to support the planning for the transition of GMP suites from the use of adherent to suspension cultures.
It appears Novartis have received US FDA Priority Review for Kymriah ( formerly CTLIO9) for adults with r/r DLBCL and EMA accelerated assessment for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK - 17 January 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis that the supplemental Biologics License Application (sBLA) for Kymriah (tisagenlecleucel, formerly CTL019) suspension for intravenous infusion for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who are ineligible for or relapse after autologous stem cell transplant (ASCT), has been accepted by the US Food and Drug Administration (FDA) for Priority Review. In addition, the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorisation Application (MAA) for Kymriah for the treatment of children and young adults with r/r B-cell acute lymphoblastic leukaemia (ALL) and for adult patients with r/r DLBCL who are ineligible for ASCT. CTL019 is a novel immunocellular therapy and a one-time treatment that uses a patient's own T cells to fight cancer.
Priority Review and accelerated assessment are granted to therapies which may provide a significant improvement in the safety and effectiveness of the treatment of a serious disease, and the designations are intended to expedite the standard review time. If approved by the FDA and EMA, Kymriah would represent the first chimeric antigen receptor T cell (CAR-T) therapy available for two distinct indications in non-Hodgkin lymphoma and B-cell ALL.
Oxford BioMedica is the sole manufacturer of the lentiviral vector that encodes CTL019. The Group signed an agreement with Novartis in July 2017 for the commercial and clinical supply of lentiviral vectors used to generate CTL019 and other undisclosed CAR-T products, for which Oxford BioMedica could potentially receive in excess of $100m from Novartis over the next three years. As announced in October 2014, Oxford BioMedica will also receive undisclosed royalties on potential future sales of Novartis CAR-T products..
You raise a valid point. However the cost of intervention has to be offset against the cost of existing treatment and care, which in the NHS is often very high!An expensive one shot treatment can therefore become economically viable.
In this regard Prosavin holds particular promise if it becomes the delivery system and drug of choice, as the costs of Parkinsons care and treatment mount significantly over the patients lifetime.
I think this is s cute piece of marketing by JD, reminding the market that theyre not only one of the only companies with manufacturing capacity but also are aiming to have a production scalability that makes the Best place to come when a company is ready to deliver a treatment stream to the market, especially with price point in mind.
Lastly Hans if you are around, as always your opinion would be most welcome as it would no doubt be more insightful than my own. I know we had a difference in the past, but that is indeed done and dusted. It would be good to have you back if you feel so inclined?
If a company wanted to deliver a gene therapy to the lung or liver, where the organs surface area is huge, the current price could be as much as $3 million per patient commercially unviable, said Mr. Dawson of Oxford BioMedica.
Oxford is improving its methods, he said, and should soon be able to cut that cost to approximately $300,000 per patient. Methods are improving, Mr. Dawson said, and his expectation is that it might cost a mere $30,000 for the viruses in the future.
Once again OXB is set to deliver on its potential, how many times have I heard that down the years. This year does look different or am I just kidding myself. The Sun Times article certainly has helped...
Having more than doubled this year to 8.85p on the back of test results that showed one of its treatments could help cure a form of childhood leukaemia, it is not necessarily an obvious choice for 2018. Nonetheless, Peel Hunt and Jefferies both have a price target of 13p per share, implying more than 40% upside.
Formal approval of the aforementioned leukaemia treatment could lead to a reappraisal of what some analysts reckon could be a $1bn blockbuster. .....
Lets hope so!!
Tends to start the year well and then fade to grey. 2018 might juts be the year!
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.